SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (129)11/13/2000 7:29:30 AM
From: Micawber  Read Replies (1) | Respond to of 447
 
Rick:

Did you see the PR on ISIP's Phase 1/2 trial of ISIS 3521 in NSCLC? Response rates look impressive until you realize that they don't say whether patient population is refractive, and when you factor in that 3521 is in combination with chemo. They really pound the table with the two complete responses. Market has yawned thus far, probably because of history of hype from these guys. Any opinions?